Institution
Scripps Health
Healthcare•San Diego, California, United States•
About: Scripps Health is a healthcare organization based out in San Diego, California, United States. It is known for research contribution in the topics: Antigen & Antibody. The organization has 7947 authors who have published 11082 publications receiving 661259 citations. The organization is also known as: Scripps.
Topics: Antigen, Antibody, Population, Virus, Gene
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The 1971 preliminary criteria for the classification of systemic lupus erythematosus (SLE) were revised and updated to incorporate new immunologic knowledge and improve disease classification and showed gains in sensitivity and specificity.
Abstract: The 1971 preliminary criteria for the classification of systemic lupus erythematosus (SLE) were revised and updated to incorporate new immunologic knowledge and improve disease classification. The 1982 revised criteria include fluorescence antinuclear antibody and antibody to native DNA and Sm antigen. Some criteria involving the same organ systems were aggregated into single criteria. Raynaud's phenomenon and alopecia were not included in the 1982 revised criteria because of low sensitivity and specificity. The new criteria were 96% sensitive and 96% specific when tested with SLE and control patient data gathered from 18 participating clinics. When compared with the 1971 criteria, the 1982 revised criteria showed gains in sensitivity and specificity.
14,272 citations
••
TL;DR: If the highest accuracy was not required, the following manipulations simplified and speeded multiple total phosphorus determinations on the eluates from column chromatographic separations.
12,381 citations
••
TL;DR: In patients with chronic hepatitis C, the most effective therapy is the combination of peginterferon alfa-2b 1.5 microg/kg per week plus ribavirin, and this randomised trial found that the benefit is mostly achieved in patients with HCV genotype 1 infections.
6,228 citations
••
Thomas Jefferson University1, Harvard University2, Scripps Health3, University of Pittsburgh4, University of British Columbia5, Memorial Hospital of South Bend6, Yale University7, Arizona Heart Institute8, University of Toronto9, St Lukes Episcopal Hospital10, Johns Hopkins University11, Lenox Hill Hospital12, University of Pennsylvania13, University of Texas at San Antonio14, Cleveland Clinic15
TL;DR: In selected patients, placement of an intracoronary stent, as compared with balloon angioplasty, results in an improved rate of procedural success, a lower rate of angiographically detected restenosis, a similar rate of clinical events after six months, and a less frequent need for revascularization of the original coronary lesion.
Abstract: Background Coronary-stent placement is a new technique in which a balloon-expandable, stainless-steel, slotted tube is implanted at the site of a coronary stenosis. The purpose of this study was to compare the effects of stent placement and standard balloon angioplasty on angiographically detected restenosis and clinical outcomes. Methods We randomly assigned 410 patients with symptomatic coronary disease to elective placement of a Palmaz-Schatz stent or to standard balloon angioplasty. Coronary angiography was performed at base line, immediately after the procedure, and six months later. Results The patients who underwent stenting had a higher rate of procedural success than those who underwent standard balloon angioplasty (96.1 percent vs. 89.6 percent, P = 0.011), a larger immediate increase in the diameter of the lumen (1.72 ±0.46 vs. 1.23 ±0.48 mm, P<0.001), and a larger luminal diameter immediately after the procedure (2.49 ±0.43 vs. 1.99 ±0.47 mm, P<0.001). At six months, the patients with stented ...
4,300 citations
••
TL;DR: In this randomized clinical trial involving patients with complex coronary lesions, the use of a sirolimus-eluting stent had a consistent treatment effect, reducing the rates of restenosis and associated clinical events in all subgroups analyzed.
Abstract: Background Preliminary reports of studies involving simple coronary lesions indicate that a sirolimus-eluting stent significantly reduces the risk of restenosis after percutaneous coronary revascularization. Methods We conducted a randomized, double-blind trial comparing a sirolimus-eluting stent with a standard stent in 1058 patients at 53 centers in the United States who had a newly diagnosed lesion in a native coronary artery. The coronary disease in these patients was complex because of the frequent presence of diabetes (in 26 percent of patients), the high percentage of patients with longer lesions (mean, 14.4 mm), and small vessels (mean, 2.80 mm). The primary end point was failure of the target vessel (a composite of death from cardiac causes, myocardial infarction, and repeated percutaneous or surgical revascularization of the target vessel) within 270 days. Results The rate of failure of the target vessel was reduced from 21.0 percent with a standard stent to 8.6 percent with a sirolimus-eluting ...
4,271 citations
Authors
Showing all 7958 results
Name | H-index | Papers | Citations |
---|---|---|---|
Eric J. Topol | 193 | 1373 | 151025 |
Stuart H. Orkin | 186 | 715 | 112182 |
Tadamitsu Kishimoto | 181 | 1067 | 130860 |
John R. Yates | 177 | 1036 | 129029 |
Tony Hunter | 175 | 593 | 124726 |
George F. Koob | 171 | 935 | 112521 |
Dennis R. Burton | 164 | 683 | 90959 |
Martin B. Leon | 163 | 1400 | 129393 |
Ian A. Wilson | 158 | 971 | 98221 |
Peter G. Schultz | 156 | 893 | 89716 |
Thomas E. Starzl | 150 | 1625 | 91704 |
Rafi Ahmed | 146 | 633 | 93190 |
Kurt Wüthrich | 143 | 739 | 103253 |
Douglas D. Richman | 142 | 633 | 82806 |
Floyd E. Bloom | 139 | 616 | 72641 |